王妍 | AMiner学者主页

全面呈现 [王妍] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（4）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Study of correlation between esophagogastric varices and Chinese medicine blood stasis syndrome

王俐琼,张玮,殷泙,黄傲霜, 史绯,杨振华,王磊,王妍,刘一博

目的:探讨慢性肝病患者食管胃底静脉曲张与血瘀证的相关性.方法:对210例慢性肝病患者进行常规胃镜检查,其中150例还接受窄波成像技术(NBI)放大内镜检查,观察血瘀证与非血瘀证组患者食管胃底静脉曲张及胃粘膜微血管变化,并应用Image-Pro Plus软件测定微血管的平均光密度值(MD).结果:①210例慢性肝病患者血瘀证者125例(59.52％),其中轻度血瘀证患者48例(22.86％)、中度血瘀证患者42例(20.00％)、重度血瘀证患者35例(16.67％);非血瘀证患者85例(40.48％).肝纤维化及肝硬化患者的血瘀证积分显著高于非血瘀证组,不同程度的血瘀证患者之间比较,差异有显著性意义.①210例患者中有53例伴有食管静脉曲张,33例出现红色征,16例出现胃底静脉曲张,30例患者胃底粘膜呈明显蛇皮征改变,28例患者出现斑疹,44例出现糜烂,门脉高压性胃病(PHG)轻型47例,PHG重型9例.③NBI胃镜下150例患者中52例胃粘膜下微血管出现内径增粗,78例患者微血管排列紊乱、42例患者微血管呈螺旋弯曲,46例患者血管内出现微血栓.血瘀证组患者微血管内径增粗发生率为43.86％、微血管排列紊乱发生率为60.53％、微血管螺旋弯曲发生率为32.46％,微血栓发生率为37.72％;非血瘀证组分别为5.56％、25.00％、13.89％、8.33％,两组比较,P＜0.05,差异有统计学意义,提示血瘀证患者胃粘膜微血管病变显著.轻、中、重度血瘀证组患者MD值为0.19±0.10、0.22±0.05、0.31±0.08;非血瘀证组MD则为0.15±0.04,组间比较,差异有显著性意义,P＜0.01.结论:慢性肝病患者随着病情加重,血瘀证程度随之加重,胃粘膜微血管形态异常如管径增粗,螺旋弯曲加重,提示胃粘膜微血管形态与血瘀证密切相关.

2018Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases（2018）引用：3

引用

AI阅读

2思美泰联合中药治疗对代偿期肝硬化患者生存质量影响的研究

陈云飞,王妍, 刘洋, 张玮, 李莹

目的:研究思美秦联合中药(治疗组)对代偿期肝硬化患者生存质量的影响,并设门冬氨酸钾镁注射液联合中药组(对照组)作为对照,为提高肝硬化患者的生存质量提供循证依据.方法:选择55例代偿期肝硬化住院患者,随机分为治疗组(30例)和对照组(25例),应用SF-36量表,CLD0及慢性肝病中医生存质量量表对两组患者治疗前后分别进行测评,并对TBI L进行治疗前后比较.结果:测评SF-36量表,治疗组在BP、MH维度治疗前后比较有统计学意义(P＜0.05X对照组在BP维度治疗前后比较亦有之(P＜0.05).两组治疗后在BP、MH维度上比较,治疗组优于对照组(P＜0.05 );测评CLDQ量表,治疗组在FA、AC、EF、WO维度治疗前后比较有统计学意义(P＜0.05),对照组在FA、EF维度治疗前后比较亦有(P＜0.05).治疗后两组在EF、WO维度上比较,治疗组显著优于对照组(P＜0.01 );在慢性肝病中医生存质量量表中,治疗组在情志,部候领域治疗前后比较有差异(P＜0.05),对照组在部候领域治疗前后比较有差烈(P＜0.05).治疗后两组在情志领域比较,治疗组优于对照组(P＜0.05);在TBIL改善上,显效率治疗组优于对照组(P＜0.05).有效率比较无统计学意义.结论:两组对肝气郁结型肝硬化患者的TBIL及相关症状改善均有疗效,但治疗组优于对照组,且在生存质量情志相关领域改善方面.治疗组有着较明显的优势.

2012Seek Medical and Ask the Medicine（2012）

引用

AI阅读

3Evaluation and clinical application of TCM quality of life scale for chronic hepatitis B

WANG YAN,WANG LEI,WANG LI-QIONG,ZHANG WEI

Objective:To assess the availability of a TCM quality of life(QOL) scale for CHB(Beta) created by our study team in a randomized controlled clinical trials.Methods:The study included 90 the damp-heat syndrome and 90 liver stagnation and spleen deficiency syndrome patients with CHB.All participants were randomized into two group,treatment group and control group.To compare the sensitivity of QOL scale with chronic liver disease questionnaire(CLDQ).Results:①CLDQ and TCM QOL scale for the respective correlation matrix result revealed a positive correlation among all items for both scales.No correlation was found among items for both scales on two two correlation matrix.②the responsibility of TCM QOL scale for CHB(Beta):There were statistically significant differences pre-and post-treatment in calibrated scale of all dimension items from TCM QOL scale in both groups(P all <0.01).In the control group,statistically significant differences pre-and 3 months post-treatment were only found in emotion subscale(P all <0.01),while the remaing dimension items and total score similar pre-and post-treatment(P>0.05).Also,statistically significant differences pre-and 6 months post-treatment could be found in calibrated scale of all dimension items from TCM QOL scale(P all <0.01).Conclusion:①The created TCM QOL scale is in an identified but relatively loose correlation to CLDQ scale due to its own specificity.②The created TCM QOL scale(Beta) has a better responsibility and sensitivity in the evaluation of QOL in patients with CHB,which could be an effective utilized in the evaluation system on the efficacy of TCM treatment in QOL of CHB.

2012Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases（2012）引用：4

引用

AI阅读

4健脾活血利水方结合托拉塞米治疗乙肝后肝硬化腹水的临床观察

王妍

通过观察健脾活血利水方结合托拉塞米对乙肝后肝硬化腹水的治疗作用,结果表明健脾活血利水方联合托拉塞米能显著改善乙肝后肝硬化腹水患者的临床表现,改善肝纤维化程度及肝功能等.

2009WORLD HEALTH DIGEST（2009）引用：1

引用

AI阅读